Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Novartis' Sandoz dips on debut after lower than expected valuation
Novartis' Sandoz dips on debut after lower than expected valuation
Novartis' Sandoz dips on debut after lower than expected valuation
Submitted by
admin
on October 4, 2023 - 9:43am
Source:
Reuters
News Tags:
Novartis
Sandoz
spinoffs
Headline:
Novartis' Sandoz dips on debut after lower than expected valuation
snippet:
Sandoz valued at 10.3 bln francs on market debut
Shares dip following debut at 24 francs apiece
Fragile stock markets make for difficult backdrop
Do Not Allow Advertisers to Use My Personal information
